Insilico Medicine (03696) Enters into Over HKD 931 Million Drug R&D Collaboration with Qilu Pharmaceutical to Accelerate Innovative Therapies for Cardiovascular and Metabolic Diseases

Stock News

Jan 27

Insilico Medicine (03696) announced that it has entered into a strategic drug research and development collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center, signing a related agreement. Through this partnership, the two parties will leverage Insilico's proprietary Pharma.AI solution to jointly develop small molecule inhibitors for specific targets, focusing on the management of cardiovascular and metabolic diseases. Under the terms of the agreement, Insilico will utilize its independently built Pharma.AI platform to concentrate on the design and optimization of novel small molecule drugs for the metabolic disease area, while Qilu Pharmaceutical will be responsible for subsequent development and commercialization activities. The total value of the agreement exceeds HKD 931 million, comprising development and sales milestone payments, as well as a single-digit tiered royalty on future net sales.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1179156628"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179156628\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179156628?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-27 08:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179156628","market":"fut","top_or_hot":-1,"title":"Insilico Medicine (03696) Enters into Over HKD 931 Million Drug R&D Collaboration with Qilu Pharmaceutical to Accelerate Innovative Therapies for Cardiovascular and Metabolic Diseases","media":"Stock News","content":"<p>Insilico Medicine (03696) announced that it has entered into a strategic drug research and development collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center, signing a related agreement. Through this partnership, the two parties will leverage Insilico's proprietary Pharma.AI solution to jointly develop small molecule inhibitors for specific targets, focusing on the management of cardiovascular and metabolic diseases. Under the terms of the agreement, Insilico will utilize its independently built Pharma.AI platform to concentrate on the design and optimization of novel small molecule drugs for the metabolic disease area, while Qilu Pharmaceutical will be responsible for subsequent development and commercialization activities. The total value of the agreement exceeds HKD 931 million, comprising development and sales milestone payments, as well as a single-digit tiered royalty on future net sales.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine (03696) Enters into Over HKD 931 Million Drug R&D Collaboration with Qilu Pharmaceutical to Accelerate Innovative Therapies for Cardiovascular and Metabolic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine (03696) Enters into Over HKD 931 Million Drug R&D Collaboration with Qilu Pharmaceutical to Accelerate Innovative Therapies for Cardiovascular and Metabolic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-27 08:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insilico Medicine (03696) announced that it has entered into a strategic drug research and development collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center, signing a related agreement. Through this partnership, the two parties will leverage Insilico's proprietary Pharma.AI solution to jointly develop small molecule inhibitors for specific targets, focusing on the management of cardiovascular and metabolic diseases. Under the terms of the agreement, Insilico will utilize its independently built Pharma.AI platform to concentrate on the design and optimization of novel small molecule drugs for the metabolic disease area, while Qilu Pharmaceutical will be responsible for subsequent development and commercialization activities. The total value of the agreement exceeds HKD 931 million, comprising development and sales milestone payments, as well as a single-digit tiered royalty on future net sales.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1179156628","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179156628","pubTimestamp":1769472974,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Insilico Medicine (03696) announced that it has entered into a strategic drug research and development collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1141":"生命科学工具和服务","03696":"英矽智能","01477":"欧康维视生物-B","BK1574":"生物医药B类股"},"translate_title":"英矽智能(03696)与齐鲁制药达成逾9.31亿港元药物研发合作加速心血管及代谢疾病创新疗法","themeId":"d697236d2e102256f5a8be78146b39b7","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"03696":1},"content_text":"Insilico Medicine (03696) announced that it has entered into a strategic drug research and development collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center, signing a related agreement. Through this partnership, the two parties will leverage Insilico's proprietary Pharma.AI solution to jointly develop small molecule inhibitors for specific targets, focusing on the management of cardiovascular and metabolic diseases. Under the terms of the agreement, Insilico will utilize its independently built Pharma.AI platform to concentrate on the design and optimization of novel small molecule drugs for the metabolic disease area, while Qilu Pharmaceutical will be responsible for subsequent development and commercialization activities. The total value of the agreement exceeds HKD 931 million, comprising development and sales milestone payments, as well as a single-digit tiered royalty on future net sales.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}